UK's Futura Medical H1 revenue rises on Haleon settlement
UK's Futura Medical H1 revenue rises on Haleon settlement
Overview
UK sexual health products developer's H1 revenue rose, driven by £1.4 mln Haleon settlement
Operating loss narrowed to £1.2 mln from £6.7 mln on lower costs and settlement income
Company warns of material uncertainties over going concern pending additional near-term funding
Outlook
Futura expects current cash to last until about October 2026 without additional funding
Company is actively pursuing funding and strategic options to strengthen its financial position
Material uncertainties remain over timing and outcome of funding initiatives, casting doubt on going concern
Result Drivers
HALEON SETTLEMENT - £1.4 mln settlement with Haleon accounted for most H1 revenue
LIMITED PRODUCT SALES - Underlying revenue mainly from US Eroxon® royalties, with EU partners selling through existing inventory
COST REDUCTION - Lower administrative expenses contributed to reduced operating loss
Company press release: ID:nRSA7679Sa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Revenue |
| GBP 1.62 mln |
|
Reuters Recommended Reads
Aug 31 - Sweden's Klaria net loss narrows on lower R&D expenses
Aug 31 - Israel's BioLineRx Q2 net loss widens on higher R&D expenses
Aug 31 - US FDA approves Takeda, Protagonist's drug for rare blood cancer
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)